These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26694593)

  • 1. Multiple clinical vertebral fractures following denosumab discontinuation.
    Anastasilakis AD; Makras P
    Osteoporos Int; 2016 May; 27(5):1929-30. PubMed ID: 26694593
    [No Abstract]   [Full Text] [Related]  

  • 2. Denosumab, osteoporosis, and prevention of fractures.
    Kyrgidis A
    N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950409
    [No Abstract]   [Full Text] [Related]  

  • 3. Denosumab, osteoporosis, and prevention of fractures.
    Kiechl S; Willeit J; Schett G
    N Engl J Med; 2009 Nov; 361(22):2188-9; author reply 2190-1. PubMed ID: 19940304
    [No Abstract]   [Full Text] [Related]  

  • 4. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
    N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab--a new option in the treatment of osteoporosis.
    Franek E
    Endokrynol Pol; 2011; 62(1):79-83. PubMed ID: 21365584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab, osteoporosis, and prevention of fractures.
    Blythe SL
    N Engl J Med; 2009 Nov; 361(22):2189-90; author reply 2190-1. PubMed ID: 19950410
    [No Abstract]   [Full Text] [Related]  

  • 7. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab, osteoporosis, and prevention of fractures.
    Blackwood J
    N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950411
    [No Abstract]   [Full Text] [Related]  

  • 9. Denosumab: new horizons in the treatment of osteoporosis.
    Wilton JM
    Nurs Womens Health; 2011; 15(3):249-52. PubMed ID: 21672176
    [No Abstract]   [Full Text] [Related]  

  • 10. [Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
    Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
    Wien Med Wochenschr; 2010 Dec; 160(21-22):586-9. PubMed ID: 21170699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab: an antifracture therapy for postmenopausal women with osteoporosis.
    Jiang X; Schnatz PF
    Menopause; 2013 Feb; 20(2):117-9. PubMed ID: 23299707
    [No Abstract]   [Full Text] [Related]  

  • 12. Denosumab: a novel antiresorptive drug for osteoporosis.
    Suresh E; Abrahamsen B
    Cleve Clin J Med; 2015 Feb; 82(2):105-14. PubMed ID: 25897599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab (prolia) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
    [No Abstract]   [Full Text] [Related]  

  • 14. Denosumab in postmenopausal women with low bone mineral density.
    Rifkin WD
    N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16742010
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
    Hiligsmann M; Reginster JY
    Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Denosumab--a new efficient osteoporosis therapy].
    Rejnmark L; Vestergaard P; Mosekilde L
    Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab in postmenopausal women with low bone mineral density.
    Schwartzman J; Yazici Y
    N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16738280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.